IDEXX executives reported share sales, including about $17.68 million sold by executive chair Jonathan Jay Mazelsky. The filings give no reason or describe a business change, so the sales alone do not show a change in IDEXX's outlook.
A sale can leave an executive with fewer shares, but the filings give no reason for these choices. They do not connect the sales to IDEXX's business or results, so this story alone does not show a change in the company's outlook.
Follow IDEXX Laboratories, Inc. (IDXX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IDXX